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Abstract. Acute myeloid leukemia (AML) is a clonal disorder of the hematopoietic stem cell, typical 
of the elderly, with a median age of over 60 years at diagnosis. In AML, older age is one of the 
strongest independent adverse prognostic factor, associated with decr
worse disease-free and overall survival, with highest rates of treatment related mortality, resistant 
disease and relapse, compared to younger patients. Outcomes are compromised in older patients 
not  only  by  increased  comorbid
recognized  that    elderly  AML  has  peculiar  biologic  characteristics  with  a  negative  impact  on 
treatment response.  
In  older  individuals  prolonged  exposure  to  environmental  carcinogens  may  be 
similarities  to  therapy-related  myeloid  malignancies  (t
previous cytotoxic treatments on hematopoietic stem cells. Age is itself a risk factor for t
are more frequent in elderly patients, wher
tumor  and  t-MN  has  been  reported.  t
elderly  AML  frequently  present  MDS
monosomal  karyotype,  and  a  myelodysplastic  phase  preceding  the diagnosis  of  overt leukemia. 
Similarly,  t-MN  and  elderly-AML  share  common  molecular  abnormalities,  such  as  reduced 
frequency of NPM1, FLT3 and CEBPA mutations and increased MDR1 expression.
Given  the  unfavorable  prognosis  of  elderly  and  t
aspects,  this  is  a  promising  field  for  implementation  of  new  treatment  protocols  including 
alternative biological drugs.
Introduction. Acute  myeloid  leukemia  (AML)  is 
mainly  a  disease  of  older  adults.  Worldwide,  AML 
affects approximately 3 to 4 individuals in 100,000 per 
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Acute myeloid leukemia (AML) is a clonal disorder of the hematopoietic stem cell, typical 
of the elderly, with a median age of over 60 years at diagnosis. In AML, older age is one of the 
strongest independent adverse prognostic factor, associated with decreased complete response rate, 
free and overall survival, with highest rates of treatment related mortality, resistant 
disease and relapse, compared to younger patients. Outcomes are compromised in older patients 
not  only  by  increased  comorbidities  and  susceptibility  to  toxicity  from  therapy,  but  it  is  now 
recognized  that    elderly  AML  has  peculiar  biologic  characteristics  with  a  negative  impact  on 
In  older  individuals  prolonged  exposure  to  environmental  carcinogens  may  be 
related  myeloid  malignancies  (t-MN),  which  result  from  toxic  effects  of 
previous cytotoxic treatments on hematopoietic stem cells. Age is itself a risk factor for t
are more frequent in elderly patients, where also a shorter latency between treatment of primary 
MN  has  been  reported.  t-MN  following  chemotherapy  with  alkylating  agents  and 
elderly  AML  frequently  present  MDS-related  cytogenetic  abnormalities,  including  complex  or 
nd  a  myelodysplastic  phase  preceding  the diagnosis  of  overt leukemia. 
AML  share  common  molecular  abnormalities,  such  as  reduced 
frequency of NPM1, FLT3 and CEBPA mutations and increased MDR1 expression.
gnosis  of  elderly  and  t-MN  and  the  similar  clinical  and  molecular 
aspects,  this  is  a  promising  field  for  implementation  of  new  treatment  protocols  including 
Acute  myeloid  leukemia  (AML)  is 
mainly  a  disease  of  older  adults.  Worldwide,  AML 
affects approximately 3 to 4 individuals in 100,000 per 
year and represents 90% of acute leukemia in adults, 
while it is rare in children. The AML incidence rises 
rapidly after 50 years, with a median age at diagnosis 
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Acute myeloid leukemia (AML) is a clonal disorder of the hematopoietic stem cell, typical 
of the elderly, with a median age of over 60 years at diagnosis. In AML, older age is one of the 
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free and overall survival, with highest rates of treatment related mortality, resistant 
disease and relapse, compared to younger patients. Outcomes are compromised in older patients 
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In  older  individuals  prolonged  exposure  to  environmental  carcinogens  may  be  the  basis  for 
MN),  which  result  from  toxic  effects  of 
previous cytotoxic treatments on hematopoietic stem cells. Age is itself a risk factor for t-MN, which 
e also a shorter latency between treatment of primary 
MN  following  chemotherapy  with  alkylating  agents  and 
related  cytogenetic  abnormalities,  including  complex  or 
nd  a  myelodysplastic  phase  preceding  the diagnosis  of  overt leukemia. 
AML  share  common  molecular  abnormalities,  such  as  reduced 
frequency of NPM1, FLT3 and CEBPA mutations and increased MDR1 expression.
MN  and  the  similar  clinical  and  molecular 
aspects,  this  is  a  promising  field  for  implementation  of  new  treatment  protocols  including 
year and represents 90% of acute leukemia in adults, 
while it is rare in children. The AML incidence rises 
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of 67 years.
1
Therapy-related AML (t-AML) accounts for 10 to 
20% of AML cases in adults. The incidence of t-AML 
is increasing due to longer life expectancy of cancer 
survivors. Therapy-related myeloid neoplasms (t-MN), 
including  t-AML  and  therapy-related  myelodisplastic 
syndromes, are now recognized as distinct nosographic 
entities according to the 2008 WHO classification of 
tumors  of  Hematopoietic  and  Lymphoid  Tissues 
(2008).
2,3
Age is a risk factor also for t-AML, which occurs at 
a  higher  median  age  compared  to  de  novo  AML.
4,5
Interestingly, patients with breast cancer treated with 
adjuvant  chemo/radiotherapy  who  develop  t-MN  are 
older at breast cancer diagnosis (mean age 60.2 years 
versus  54.5  years;  P  =  0.01),
6 and  older  age  at  the 
primary cancer diagnosis has been associated to shorter 
latency  to  t-MN  development.
7 History  of  multiple 
cancer  and familial  history  of  neoplastic  diseases 
represent additional risk factors for t-MN.
6
This  review  will  focus  on  similarities  between 
elderly  and  therapy-related  AML,  both  from  the 
clinical and biological point of view. These diseases 
are  commonly  associated  to  worse  prognosis  related 
both to tumor biology and host-related factors. Tumor 
biology  is  characterized  by  adverse  prognostic 
signature  affecting  cytogenetics,  molecular  genetics, 
epigenetics, GEP, and multidrug resistance (Table 1). 
Similarly,  compared  to  de  novo AML  in  younger 
patients,  elderly  patients  and  those  with  t-MN  more 
often  present  significant  comorbidities,  reduced 
tolerance to treatment, higher incidence of treatment-
related  complications  and  are  commonly  excluded 
from treatment protocols.  
In this review, we will use the terms “AML in older 
patients”  and  “elderly  AML”  to  indicate  AML 
occurring in individual aged 60 years or more. Changes 
of  leukemia  features  will  be  described  according  to 
patients’  age  considering  different  age  intervals. 
Nevertheless,  aging  is  a  continuum  of  changes 
affecting not only individuals, but also several aspects 
of  diseases.  In  particular,  leukemia  biological  and 
clinical features change gradually with aging without 
any  sharp  distinction  or  any  universally  accepted 
temporal watershed to define distinct disease subsets.
Morphological  and  Cytogenetic  Aspects. 
Morphological/laboratory  characteristics  as  well  as 
clinical course present several similarities between t-
AML and elderly AML. Cytological and cytochemical 
differences have been described between “young” and 
elderly    AML,  indicating  a  less  differentiated 
phenotype for “elderly” blasts.
8 Elderly AML usually 
presents  with  lower  white  blood  cell  (WBC)  counts 
compared  to  younger  patients  (12,510/μl  versus 
19,800/μl,  P <  .001).
9 Similarly,  t-AML  have  lower 
WBC count at diagnosis, compared to de novo AML 
(7400/μl versus 12500/μl, respectively, P = 0.003).
4
The WHO Classification of Myeloid Malignancies 
identifies  AML  with  myelodysplasia-related  changes 
(AML-MRC) as a distinct AML subclass when at least 
one of the following prerequisites is fulfilled: a history 
of  secondary  AML arising  from a  previous MDS or 
MDS/MPN,  AML  with  MDS-related  cytogenetic 
abnormalities, and/or AML with multilineage dysplasia 
(MLD).
3 The  presence  of  MDS-related  cytogenetic 
abnormalities and/or a MDS or MDS/MPN history is 
associated to older age (69.8 years versus 65.6 years, P 
= 0.011), lower median WBC count (6300/ μl versus 
13800/μl,  P <  0.001)  and  worse  median EFS  (10.7 
months versus 16.9 months; P = 0.005) and OS (16.8 
months versus not reached; P = 0.001).
10 This confirms 
the impact of a previous history of MDS or of typical 
cytogenetics, as one of the main biological factors in 
AML. 
Two distinct t-AML subtypes have been described 
according to the previous cytotoxic therapy.
2,3 Those t-
AML  occurring  5-10  years  after  the  exposure  to 
alkylating  agents  and/or  ionizing  radiation  present 
several similarities with elderly AML. These patients 
commonly  present  a  myelodysplastic  phase  (t-MDS) 
and  bone  marrow  failure  with  one  or  multiple 
cytopenias before evolving into  overt leukemia. This 
subset of t-AML is commonly associated with MDS-
related cytogenetic abnormalities, such as monosomies 
or partial deletions of chromosome 5 and/or 7. On the 
contrary, a smaller subset of t-AML occurring at 1-5 
years  after  exposure  to  topoisomerase  II  inhibitors, 
does not have a myelodysplastic phase but presents as 
overt leukemia and is often associated with balanced 
chromosomal translocations. It could be hypothesized 
that limited amounts of genetic and epigenetic events 
could  be implicated in  the  pathogenesis  of the latter 
type of t-AML, while t-MN following alkylating agents 
requires  a  longer  latency  period  and  probably  a 
multistep  accumulation  of  genetic  and  epigenetic 
events that finally result in overt leukemia.
2,3
Cytogenetics has been indicated as the most powerful 
outcome  predictor  in  AML,  independent  of  age  and 
other  potential  confounders.
11 Elderly  AML  and  t-
AML share common cytogenetic aspects. Elderly AML 
is  associated  to  increasing  incidence  of  unfavorable 
complex  karyotypes  and  a  decreasing  incidence  of 
favorable  balanced  chromosomal  translocations.
9,12,13
In a large study evaluating the age-specific incidence 
of  cytogenetic  abnormalities  in  2555  patients  with 
AML  between  21  and  70  years  of  age,  adverse 
cytogenetic  profiles  were  disproportionately  seen  in 
elderly  patients,  while  balanced  translocations 
decreased and unbalanced aberrations increased with Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Table 1. Similarities between elderly and therapy-related AML
Similarities AML in older patients * t-AML**
Morphology 
and Clinics
Frequent history of a myelodysplastic phase and 
common myelodysplasia-related changes
Lower WBC count
Frequent history of a myelodysplastic phase and common 
myelodysplasia-related changes (if previous exposure to 
alkylating agents and radiation)
Lower WBC count
Cytogenetic Frequent adverse cytogenetics
(-5/5q-, -7/7q-, complex, monosomal)
Frequent adverse cytogenetics
(-5/5q-, -7/7q-, complex, monosomal)
Molecular
Lower frequency of  FLT3, NPM1, CEBPA 
mutation;  
Higher frequency of TET2, DNMT3A, IDH1 and 
IDH2 mutation
No differences in RUNX1 and  NRAS mutation 
frequency.
Lower frequency of  FLT3, NPM1, CEBPA, TET2 mutation;
Unknown DNMT3A, IDH1 and IDH2 mutation frequency.
Higher RUNX1 mutation frequency
No difference in  NRAS mutation frequency
Biology
High MDR1 expression 
Distinct GEP
Shorter telomere length compared to normal BM, but 
not to AML in younger patients
High MDR1 expression
Distinct GEP
Shorter telomere length
Higher frequency of gene promoter hypermethylation
* Compared to AML in younger patients
** Compared to de novo AML
age.
12 Similarly, in 1284 patients with AML aged 18 to 
85  years,  a  lower  incidence  of  favorable  karyotypes
and  a  higher  incidence  of  unfavorable  complex 
karyotypes were seen in patients aged over 60 years.
9
Monosomal kayotype (MK), defined as 2 or more 
distinct  monosomies  or  a  single  monosomy  in  the 
presence of other structural abnormalities, identifies a 
distinct  subset  of  AML  with  an  extremely  poor 
prognosis and a 4-year OS of 3-4%, even worse than 
that of unfavorable cytogenetics .
14,15 The proportion of 
patients  with  MK-AML  including  -5/5q- and  -7/7q-
increases with age, from 4% in patients younger than 
30  years  to  20%  in  those  older  60  years  of  age  or 
more.
15
In  the  same  line,  t-AML  frequently  present 
abnormal karyotype (75% versus 51%, P < .0001) and 
adverse  cytogenetics  (39%  versus  19%,  P <  .0001). 
The  frequency  of  favorable-risk  abnormalities  is 
similar  in  t-AML  and  de  novo AML,  while  the 
intermediate risk category is less frequent in t-AML. 
Common  poor  risk  cytogenetic  abnormalities 
significantly enriched in t-AML group include t(9;11), 
-5/5q-, -7/7q-, abnormalities (17p), complex karyotype 
and monosomal karyotype.
4 A trend toward a higher 
representation  of  trisomy  8  outside  a  complex 
karyotype has also been reported in t-AML.
4
Recurrent Molecular Abnormalities. Heterogeneous 
data  have  been  published  about  the  prevalence  of 
NMP1 mutation in elderly AML. On the other hand, 
FLT3 internal tandem duplications (ITD) were shown 
to  be  less  common  in  elderly  compared  to  younger 
AML patients (23% and 37%).
16 Both NPM1 mutation 
and  FLT3  ITD  have  been  reported  to  be  under-
represented  in  elderly  normal  karyotype  AML 
compared to younger patients (52.1%  and 66.4% for 
NPM1  mutation;  26.6%  and  37.2%  for  FLT3-ITD, 
respectively).
9 The frequency of both NPM1 mutations 
and  FLT3-ITD  are  significantly  lower  in  t-AML 
compared to de novo AML, indicating that secondary 
leukemogenesis  might  follow  mechanisms  different 
from  those  seen  in  de  novo AML.  Nevertheless,  in 
cytogenetically normal AML, no difference was found 
in the incidence and distribution of mutated NPM1 and 
FLT3-ITD in t-AML and de novo AML.
4
TET2 mutations occur in 23% of AML patients and 
are  associated  with  older  age  (P < .001).  The 
prevalence of TET2 mutations gradually increased with 
age,  from  7%  in  adults  younger  than  30  to  32%  in 
patients aged 70 years or older (P  < .001).
21 Mutation 
of at least one copy of the TET2 gene was detected in 
49/247 (19.8%) patients with secondary acute myeloid 
leukemia, including both AML with MRC (n=201) or 
therapy-related (n=46) leukemias. In this study, TET2 
mutations were significantly less frequent in therapy-
related (8.7%) than MRC (22.3%; P = 0.035) AML.
18
DNMT3A  mutations  occur  in  22%  of  AML 
patients, are highly enriched in the group of patients 
with an intermediate-risk cytogenetic profile, and are 
associated to shorter overall survival. Patients carrying 
DNMT3A mutations have a higher median age at the 
diagnosis compared to unmutated patients.
19 There are 
no data on the incidence of DNMT3A mutation in t-
AML.
Isocitrate  dehydrogenases  IDH1  and  IDH2 
mutations,  which  lead  to  accumulation  of  2-
hydroxyglutarate  in  neoplastic  cells,  are  recurrent  in 
AML  patients  (about  16%  of  AML  patients), 
particularly  in  those  with  normal  cytogenetics  and 
NPM1  mutated,  and  have  an  unfavorable  impact  on Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
outcome.  Patients  carrying  IDH  mutations  present  a 
higher median age at diagnosis compared to IDH wild-
type patients.
20,21
CEBPA mutations occur in 6-15% of AML patients 
and  are  more  common  in  patients  with  normal 
kayotype.  Double  CEBPA-mutant  have  a  better 
prognosis  compared  to  wild-type  and  single  mutant. 
Frequency  of  double  CEBPA  mutation  decrease  by 
increasing age.
22 CEBPA mutations are uncommon in 
t-MN.
23 RUNX1  mutations  occur  in  5.6%  of  AML 
patients  with  no  difference  in  frequency  among 
different age groups.
24 RUNX1 mutation are common 
in t-MN (15.7% in a cohort of 140 patients) and are 
commonly  associated  to  previous  therapy  with 
alkylating agents and chromosome 7 deletion.
25 NRAS 
mutations  occur  in  10.3%  of  AML  patients  with  no 
differences according to age and between de novo and 
therapy-related AML.
26 WT1 mutations occur in 6.8% 
of  AML  patients  and  are  closely  associated  with 
younger age
27 and are uncommon in t-MDS/AML.
28
Disease  Behaviour  and  Biology.  Several  adjunctive 
molecular  features  make  elderly  and  therapy-related 
AML  biologically  different  from  de  novo AML  in 
younger  patients,  involving  multidrug  resistance, 
telomere  shortening,  gene  expression  profiling  and 
gene promoter methylation.
P-glycoprotein  (Pgp)  is  a  membrane  transporter 
encoded by the multidrug resistance (ABCB1, MDR1) 
gene,  which  traps  hydrophobic  drugs,  including  key 
chemotherapeutic drugs  in the plasma membrane of 
cells  and  effluxes  them  using  an  ATP-dependent 
process. High Pgp expression is detected in about 50% 
of  AML  blast  samples,  is  more  common  in  older 
(71%), than in younger cohorts (35%) and is associated 
with poor response to chemotherapy.
29,30 Similarly to 
elderly AML, secondary leukemias present higher Pgp 
expression compared to de novo AML (61 versus 37, P
< 0.001),
31 which may lead to reduced responsiveness 
to chemotherapy and chemoresistance.
Telomeres  are  specialized structures  composed  of 
TTAGGG  repeats  and  associated  proteins  located  at 
the end of eukaryotic chromosomes. Telomere repeats 
are lost with each cell division, eventually leading to 
genetic  instability  and  cellular  senescence  when 
telomeres  become  critically  short.  Age-adjusted 
telomere  length  in  AML  patients  is  significantly 
shorter than in matched healthy controls. Surprisingly, 
patients younger than 60 years had significantly shorter 
age-adjusted telomere length than patients older than 
60 years (median: -3.4 vs. -1.7 telomere fluorescence 
units,  TFU;  P<0.001),  while  age-adjusted  telomere 
length was found to be significantly shorter in patients 
displaying an aberrant karyotype than in patients with a 
normal  karyotype  (median  -3.0  vs.  -2.3  TFU; 
p=0.03).
32 The development of t-MDS/AML has been 
associated  with  and  preceded  by  markedly  altered 
telomere dynamics in hematopoietic cells. Accelerated 
telomere  shortening  in  patients  developing  t-
MDS/AML  is  associated  to  genomic  instability  and 
may  contribute  to  leukemic  transformation.
33 In 
experimental  models,  irradiation  and  chemotherapy 
were able to induce persistent and progressive telomere 
shortening and DNA damage accrual, reproducing the 
effects of aging in the hematopoietic system.
34,35
Elderly AML also display a distinct gene expression 
profiling (GEP) compared to younger AML patients. In 
a cohort of 525 adult AML, the transcriptome of the 
175 oldest patients (median age 59.4 years) compared 
to that of  the 175 youngest patients (median age 31.1 
years) revealed 969 differentially expressed probe sets, 
of  whom  477  were  up-regulated  and  492  down-
regulated  with  increasing  age.  The  Gene  Ontology 
analysis of 145 “Up-with-Age” as well as 257 “Down-
with-Age” probe sets revealed that genes involved in 
biologic processes, as regulation of I-κB kinase NF-κB 
cascade and immune response were up-regulated with 
increasing age. On the other hand, biologic processes 
as  establishment  or  maintenance  of  chromatin 
architecture,  regulation  of  cyclin-dependent  protein 
kinase  activity,  and  cell  matrix  and  cell-substrate 
adhesion  were  found  to  be  downregulated  with 
increasing  age.  In  particular,  among  differentially-
expressed  genes,  p16INK4A,  encoded  by  the  tumor-
suppressor  gene  CDKN2A,  is  down-regulated  in 
elderly  AML  samples,  while  it  is  normally  induced 
during  the  physiologic  aging  of  hematopoietic  stem 
cells.
36 Similarly, the analysis of oncogenic signaling 
pathway  showed  that  older  patients  have  a  lower 
probability of E2F and PI3-kinase pathway activation,
but a higher probability of RAS, TNF, Src, and EPI 
pathway activation. Using genomic-derived signatures 
of anthracycline-sensitivity, elderly patients presented 
a  uniformly  anthracycline  resistant  signature 
irrespective of tumor biology, while younger patients 
were much more likely to be sensitive to adriamycin.
37
According to GEP, two distinct t-AML subgroups 
have  been  identified:  the  first  group  associated  with 
del5q/-5 shows a higher expression of genes involved 
in  cell  cycle  control  (CCNA2,  CCNE2,  CDC2), 
checkpoints  (BUB1),  or  growth  (MYC),  and  loss  of 
expression  of  the  gene  encoding  IFN  consensus 
sequence-binding protein (ICSBP). The second t-AML 
group  is  characterized  by  down-regulation  of 
transcription  factors  involved  in  early  hematopoiesis 
(TAL1,  GATA1,  and  EKLF)  and  overexpression  of 
proteins  involved  in  signaling  pathways  in  myeloid 
cells  (FLT3)  and  cell  survival  (BCL2).  Moreover 
CD34+ cells from patients with t-AML present a more 
immature profile than normal CD34+ cells.
38Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Epigenetic changes, in particular DNA methylation, 
are  recognized  as  significant  contributors  to 
leukemogenesis,  and  in  particular  in  therapy-related 
diseases.  By  a  single  gene  analysis  of  promoter 
hypermetylation  of  several  tumor-suppressor  genes, 
BRCA1  and  DAPK1  were  found  more  frequently 
hypermethylated  in  therapy-related  than  in  de  novo 
AML,  while  no  significant  differences  were  found 
according to patients’ age.
39-42 In 356 patients studied 
for  concurrent  methylation  of  several  promoters,  t-
MDS/AML  were  significantly  more  frequently 
hypermethylated in 2 or more  promoter regions than 
de  novo MDS  or  AML  (17%  vs  11.5%  and  9.5%, 
p=0.035).
42 Moreover,  the  methylation  profile  of 
14,000 promoters in MDS and secondary AML have 
showed  that  these  diseases  display  more  extensive 
aberrant  DNA  methylation  involving  thousands  of 
genes  than  normal  CD34+  bone  marrow  cells  or  de 
novo AML blasts. This aberrant methylation affected 
particular  chromosomal  regions,  occurred  more 
frequently in Alu-poor genes, and included prominent 
involvement of genes involved in the WNT and MAPK 
signaling pathways.
43
Treatment Outcome. The most significant similarity 
between  elderly  and  t-AML  is  the  poor  prognosis, 
compared to younger and de novo AML. 
Older age is a major adverse prognostic factor for 
AML in general. Surveillance, Epidemiology, and End 
Results (SEER) statistics from 1996 to 2002 show 5-
year relative survival rates of 34.4% for  adults aged 
under  65  and  4.3%  for  those  over  65  years.
13 A 
retrospective analysis of 968 patients with previously 
untreated AML in 5 Southwest Oncology Group trials 
compared  treatment  outcome  by  stratifying  patients 
into  4 different  age groups (<56,  56–65, 66–75, and 
>75 years). The CR rates decreased from 64%, to 46%, 
39%, and 33%, respectively, while the median overall 
survival  was  18.8,  9.0,  6.9,  and  3.5  months, 
respectively.  In  responding  patients,  median  disease-
free  survival  was  21.6,  7.4,  8.3,  and  8.9  months, 
respectively.
44 In the same analysis, age had a modest 
effect in patients with an excellent performance status 
(PS), but for patients with a PS of 2 or 3, age had a 
dramatic effect, with 82% of patients older than 75 and 
a PS of 3 dying within 30 days from induction start .
44
In the last three decades significant improvement in 
survival  has been mainly  observed in  younger  AML 
patients.  In a  large  Swedish  population-based  cohort 
study including 9729 AML patients diagnosed between 
1973 and 2005, one-year survival increased across all 
age categories, but the improvement in 5- and 10-year 
AML survival was confined to patients younger than 
80 years and was most prominent in the young (<60 
years) patient population.
45
Similar to elderly AML, patients with t-AML are 
often  precluded  from  intensive  treatment  due  to 
frequent  comorbidities  and  cumulative  toxicities, 
related  to  previous  cytotoxic  treatments.  Also  when 
appropriately treated as de novo AML, t-AML still has 
worse  outcome.  According  to  the  analysis  of  6 
prospective multicenter treatment trials of the German-
Austrian AMLStudy Group (AMLSG), 4-year relapse-
free survival  was 24.5% in t-AML and 39.5% in de 
novo AML and 4-year overall survival was 25.5% and 
37.9% (age-stratified log-rank test P = .001 for both). 
In multivariate analysis, t-AML remained an adverse 
prognostic factor for death in complete remission, but 
not relapse, and overall survival in younger intensively 
treated patients. On the other hand it predicted relapse, 
but  not  death  in  complete  remission,  in  older,  less 
intensively treated patients. In more intensively-treated 
younger adults, treatment-related toxicity had a major 
negative  impact  on  outcome,  possibly  reflecting 
cumulative toxicity of cancer treatment.
4
An  analysis  matched  for  age,  ECOG  PS  and 
additional  cytogenetic  abnormalities,  compared  de 
novo and therapy related Core Binding Factor (CFB) 
AML, carrying the recurrent chromosomal aberrations 
inv16  or  t(8;21).  An inferior treatment  outcome  was 
observed  in  patients  with  t-AML,  with  a  median 
overall survival of 100 weeks compared to 376 weeks 
in  de  novo CBF  AML  (P =  .001).
46 The  negative 
prognostic  role  of  t-AML  in  inv16  AML  has  been 
confirmed also by the AMLSG prospective trials.
4 On 
the other hand, favorable karyotype t-AML, including 
t(15;17)  and  t(8;21),  treated  according  to  standard 
protocols,  had  an outcome similar  to  de  novo cases, 
indicating  the  dominant  prognostic  role  of  good 
karyotypes.
4
Treatment  Implications.  Besides  biological  factors 
associated to a more aggressive disease behavior, host 
related  factors, including  performance and functional 
status,  cumulative  toxicities  and  comorbity 
significantly impact on prognosis, treatment tolerability 
and  complications.  Both  elderly  and  therapy-related 
AML  are  associated  with  reduced  bone  marrow 
hematopoietic cell reserve, due to physiological aging-
related  bone  marrow  impairment  or  to  the  effect  of 
previous  cytotoxic  treatment,  respectively.  This 
hampers  patients  to  overcome  intensive  treatment  or 
makes  recovery  time  longer  than  that  of  younger 
patients with de novo AML, so that most patients have
to interrupt treatment after induction chemotherapy due 
to  complications.  Notwithstanding,  t-AML  patients 
with  good  performance  status,  favorable  karyotypes 
and without significant comorbidities should still take 
advantage from standard therapy, since response rates 
are similar to younger patients with de novo AML. All Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
these aspects should accurately be taken into account 
during treatment decision-making. 
Before starting treatment, elderly leukemic patients 
should  undergo  comprehensive  geriatric  assessment 
(CGA)  to  identify  problems  that  may  interfere  with 
cancer  treatment,  as  recommended  by  the  NCCN 
guidelines.
13 Comorbidity burden significantly impacts
on  response  rate,  treatment-related  toxicity  and 
survival.  The  use  of  standardized  comorbidity 
assessment  tools  can  help  to  stratify  patients  and 
identify  those  who  are  less  likely  to  benefit  from 
standard  therapies.  Both  the  Charlson  Comorbidity 
Index  (CCI)  and  the  Hematopoietic  Cell 
Transplantation  Comorbidity  Index  (HCT-CI)  were 
able to identify patients with higher score associated 
with an adverse prognosis.
48,49
Evaluation  of  physical  function  provides 
information  independent  of  comorbidity  in  older 
patients with AML. Score systems, such as the Eastern 
Cooperative  Oncology  Group  (ECOG)  and  the 
Karnofsky performance  status  scales  and  the  Basic 
Activities  of  Daily  Living  (ADL)  and  Instrumental 
Activities of  Daily Living (IADL) scales,  can detect 
subclinical disability that might predict tolerability and 
response.
13
Although the optimal therapy for older patients with 
AML remains debated, there is some evidence to guide 
decision making for  individual patients. Older adults 
with newly diagnosed AML who present with any of 
the  following  characteristics  are  more  likely  to 
experience  toxicity  and  less  likely  to  benefit  from 
standard induction chemotherapy: an ECOG score >2, 
significant comorbidity (CCI score >1, HCT-CI score 
>2), and poor risk cytogenetics. It would be reasonable 
to  offer  these  patients  supportive  care  alone,  low-
intensity therapy, or a clinical trial investigating novel 
agents. Alternatively, older adults with good functional 
status  (ECOG  score  <  2,  no  impairment  in  IADLs), 
minimal  comorbidity, and  good-risk  cytogenetics  are 
likely  to  benefit  from  standard  curative  therapies 
regardless of chronologic age. The optimal treatment 
for the large majority of older adults falling between 
these two extremes is unclear.
5,13
Similarly  to  elderly  AML,  patients  with  t-AML 
should be accurately evaluated for performace status, 
comorbidities,  status  of  the  primary  disease  and 
presence  of  complications  from  primary  therapy,  as 
well  as  for  cytogenetic  abnormalities.  Patients  with 
therapy-related  acute  promyelocytic  leukemia  (APL) 
should  be  treated  as  patients  with  de  novo  APL. 
Patients  with  t-AML associated  with  other  favorable 
karyotypes  should  receive  standard  induction 
chemotherapy  followed  by  high-dose  cytarabine 
consolidation.  Patients  with  indermediate  and 
unfavorable cytogenetics who have an HLA-matched 
donor  should  be  considered  for  allogeneic  HCT. 
Supportive care or low dose chemotherapy remain the 
gold  standard  for  patients  with  poor  performance 
status.
50,51
New investigational treatment approaches are under 
consideration  for  t-AML  and  elderly  AML  patients, 
including  hypomethylating  agents  which  induce 
significant  response  rates  with  limited  toxicity  in 
patients  with  unfavorable  biologic  factors  and  not 
susceptible of intensive chemotherapy.
5,13,50,51
Conclusions.  The  different  biology  of  elderly  AML 
favors  the  hypothesis  of  the  involvement  of  specific 
pathogenetic  pathways  in  this  disease,  similar  to 
therapy-related  AML.  De  novo AML  in  younger 
patients, especially those with “balanced” karyotypes, 
are  thought  to  result  from  a  limited  number  of 
mutational events restricting the diversity of leukemia 
subclones  and  leaving many  cell  functions  relatively 
intact. In contrast, AML in the elderly may more often 
be the result of a string of mutational events leading to 
multiple  leukemic  subclones  with  the  opportunity  to 
develop multiple mechanisms of chemoresistance.
52
Both  elderly  and  t-AML  take  their  origin  by  the 
physiological  or  treatment-induced  aging  process  of 
bone  marrow  hematopoietic  system  and 
microenvironment, associated to reduced efficiency of 
DNA repair system, reduced hematopoietic reserve and 
immune  surveillance,  and  prolonged  exposure  to 
carcinogens  (environmental  or  cytotoxic  agents  and 
irradiation, respectively).  
New therapeutic development are needed, because 
actual therapy strategies are limited due both to host-
related factors responsible of poor tolerance to standard 
chemotherapy,  and  adverse  biological  features 
associated to treatment resistance .
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